DXCM Earnings Date: Feb 11, 2027 (Estimated) — DexCom, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is DXCM's next earnings date?
DexCom, Inc. (DXCM) is expected to report Q4 2026 earnings on Thursday, February 11, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.73 on revenue of $1.40B.
How did DXCM do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), DexCom, Inc. posted EPS of $0.73 versus the $0.68 estimate, a beat of 8.2%. Revenue was $1.34B against a $1.33B estimate.
How much does DXCM stock move after earnings?
DXCM beat EPS estimates in 6 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 9.8% (up or down) in the day after earnings.
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
🤖 AI Earnings Analysis
Dexcom’s G7 15-day launch in Canada extends its competitive CGM reach, while Q3 results were solid: revenue rose 8% to $1.3B and EPS increased to $0.73 from $0.61, beating estimates by $0.05.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 0.68 | 0.73 | +8.15% | $1.34B | ✅ Beat | — | — | — |
| 2026-07-30 | Q2 2026 | 0.61 | 0.70 | +14.75% | $1.31B | ✅ Beat | +11.95% | +11.38% | +21.84% |
| 2026-04-30 | Q1 2026 | 0.47 | 0.56 | +19.15% | $1.19B | ✅ Beat | +3.02% | +2.28% | +25.73% |
| 2026-02-12 | Q4 2025 | 0.65 | 0.68 | +4.62% | $1.26B | ✅ Beat | +7.59% | +12.29% | +1.94% |
| 2025-10-30 | Q3 2025 | 0.57 | 0.61 | +7.02% | $1.21B | ✅ Beat | -14.63% | -14.93% | -6.86% |
| 2025-07-30 | Q2 2025 | 0.45 | 0.48 | +6.67% | $1.16B | ✅ Beat | -9.31% | -14.22% | -15.70% |
| 2025-05-01 | Q1 2025 | 0.33 | 0.32 | -3.03% | $1.04B | ❌ Miss | +16.17% | +21.46% | +21.71% |
| 2025-02-13 | Q4 2024 | 0.50 | 0.45 | -10.00% | $1.11B | ❌ Miss | +5.92% | +5.58% | -15.15% |
Showing last 8 quarters.